phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Moffitt Study Finds Promising First Evidence of Targeted Therapy for NRAS-Mutant Melanoma

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and activate the immune system, offering the first targeted approach for patients with NRAS-mutant melanoma, an aggressive form of skin cancer with limited treatment options beyond immune checkpoint inhibitors. Results from the study were published in Cancer Immunology Research. It shows the potential for durable responses, laying the groundwork for future clinical trials and a possible new standard of care.

November 4, 2025


November 5 2025

November 4 2025

November 3 2025

November 2 2025

November 1 2025

October 31 2025

October 30 2025

October 29 2025

October 28 2025

October 27 2025

October 26 2025

October 25 2025

October 24 2025

October 23 2025

October 22 2025

Angell Street Psychiatry
Copyright 2025 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy